Phaseline

Companies › Cantex Pharmaceuticals

Cantex Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 2 Phase 2, 2 Phase 1; Infectious disease, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Azeliragon
Advanced glycosylation end product-specific receptor antagonist
AGERPhase 2Glioblastoma; COVID-19; Cancer Related Cognitive Decline; Solid TumorDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05815485AzeliragonPhase 2COVID-19Infectious diseaseApr 2026
NCT05256745AzeliragonPhase 1Cancer Related Cognitive DeclineOncologyDec 2026
NCT05986851AzeliragonPhase 2GlioblastomaOncologyDec 2026
NCT06724926AzeliragonPhase 1Solid TumorOncologyJan 2027

Targets

AGER (1)

Companies with the same targets

Arrowhead Pharmaceuticals

Companies built like this

Tetraphase Pharmaceuticals Amivas The Skin Center Dermatology Group Shanghai Jiatan Pharmatech Shanghai Guangsheng Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.